BioTime (Israel) Performance

BTX -- Israel Stock  

ILS 558.20  11.50  2.02%

BioTime holds performance score of 15 on a scale of zero to a hundred. The firm shows Beta (market volatility) of -0.2283 which signifies that as returns on market increase, returns on owning BioTime are expected to decrease at a much smaller rate. During bear market, BioTime is likely to outperform the market. Although it is essential to pay attention to BioTime historical returns, it is also good to be reasonable about what you can actually do with equity current trending patterns. Macroaxis philosophy towards foreseeing future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if BioTime expected return of 1.8915 will be sustainable into the future, we have found twenty-one different technical indicators which can help you to check if the expected returns are sustainable. Use BioTime Jensen Alpha as well as the relationship between Potential Upside and Skewness to analyze future returns on BioTime.
Horizon     30 Days    Login   to change

BioTime Relative Risk vs. Return Landscape

If you would invest  37,000  in BioTime on February 20, 2019 and sell it today you would earn a total of  18,820  from holding BioTime or generate 50.86% return on investment over 30 days. BioTime is generating 1.8915% of daily returns assuming 8.2191% volatility of returns over the 30 days investment horizon. Simply put, 73% of all equities have less volatile historical return distribution than BioTime and 66% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
      Risk (%) 
Assuming 30 trading days horizon, BioTime is expected to generate 12.64 times more return on investment than the market. However, the company is 12.64 times more volatile than its market benchmark. It trades about 0.23 of its potential returns per unit of risk. The DOW is currently generating roughly 0.19 per unit of risk.

BioTime Market Risk Analysis

Sharpe Ratio = 0.2301
Good Returns
Average ReturnsBTX
Small Returns
Negative Returns

BioTime Relative Performance Indicators

Estimated Market Risk
  actual daily
 73 %
of total potential
Expected Return
  actual daily
 34 %
of total potential
Risk-Adjusted Return
  actual daily
 15 %
of total potential
Based on monthly moving average BioTime is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioTime by adding it to a well-diversified portfolio.

BioTime Performance Rating

BioTime Risk Adjusted Performance Analysis


Risk-Adjusted Performance

Compared to the overall equity markets, risk-adjusted returns on investments in BioTime are ranked lower than 15 (%) of all global equities and portfolios over the last 30 days.

BioTime Alerts

Equity Alerts and Improvement Suggestions

BioTime appears to be very risky and stock price may revert if volatility continues
The company reported revenue of 5.23M. Net Loss for the year was (72.97M) with profit before overhead, payroll, taxes, and interest of 3.29M.
BIOTIME has accumulated about 21.44M in cash with (30.75M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.17.
Roughly 46.0% of the company shares are held by company insiders

BioTime Performance Indicators

BioTime Basic Price Performance Measures

Quick Ratio7.80
Fifty Two Week Low319.90
Fifty Two Week High1,113.00
Check also Trending Equities. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.